copertina di Defining Optimal Immunotherapies for Type 1 Diabetes: Novartis Foundation Symposium, ...

Defining Optimal Immunotherapies for Type 1 Diabetes: Novartis Foundation Symposium, Volume 292

di Novartis Foundation • 2008 • dettagli prodotto

spedizione gratuita
normalmente disponibile
per la spedizione in 10-15 giorni lavorativi

da €142,80 a € 135,66

Paga gli acquisti tra 30€ e 2.000€ in 3 rate
senza interessi. Scopri di più

Aggiungi al carrello
Aggiungi alla lista dei desideri

DESCRIZIONE

This book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D). Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials. The book integrates information from human and animal studies. The book considers T1D within the broader context of autoimmune disease. The format contains several discussions, which address specific questions and provides guidelines for future strategies and solutions for discovering a cure.1. Michael Rutter Introduction: whither gene–environment interactions? 2. Rudolf Uher Gene–environment interaction: overcoming methodological challenges Discussion 3. Marco Battaglia, Cecilia Marino, Michel Maziade, Massimo Molteni and Francesca D’Amato Gene–environment interaction and behavioural disorders: a developmental perspective based on endophenotypes Discussion 4. Naomi R. Wray, William L. Coventry, Michael R. James, Grant W. Montgomery, Lindon J. Eaves and Nicholas G. Martin Use of monozygotic twins to investigate the relationship between 5HTTLPR genotype, depression and stressful life events: an application of Item Response Theory Discussion Appendix General discussion I 5. Harold Snieder, Xiaoling Wang, Vasiliki Lagou, Brenda W. J. H. Penninx, Harriëtte Riese and Catharina A. Hartman Role of gene–stress interactions in gene-finding studies Discussion 6. Kenneth A. Dodge Practice and public policy in the era of gene–environment interactions Discussion 7. Kristi B. Adamo and Frédérique Tesson Gene–environment interaction and the metabolic syndrome Discussion General discussion II 8. Stephen P. Robertson and Richie Poulton Longitudinal studies of gene–environment interaction in common diseases—good value for money? Discussion 9. Kee-Seng Chia Gene–environment interactions in breast cancer Discussion 10. Malak Kotb, Nourtan Abdeltawab, Ramy Aziz, Sarah Rowe, Robert W. Williams and Lu Lu Unbiased forward genetics and systems biology approaches to understanding how gene–environment interactions work to predict susceptibility and outcomes of infections Discussion 11. Steven R. Kleeberger and Hye-Youn Cho Gene–environment interactions in environmental lung diseases Discussion General discussion III 12. Fernando D. Martinez Gene–environment interaction in complex diseases: asthma as an illustrative case Discussion 13. Michael Rutter Conclusions: taking stock and looking ahead Glossary Index of contributors Subject index